Business
Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand
TORONTO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (&#x...
About this update from Profound Medical Corp
[{"type":"text","content":"Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand\n\n\n\n TORONTO, Nov. 12, 2025 (GLOBE NEWSWIRE) --\n \n Profound Medical Corp.\n \n (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today that it has entered into an exclusive distribution and supply agreement for its TULSA-PRO\n \n ®\n \n system with Getz Healthcare, a leading distributor of medical devices, equipment and consumables, in Australia and New Zealand.\n \n\n The\n \n TULSA Procedure™\n \n , performed using Profound’s\n \n TULSA-PRO\n \n system, is a significant advancement in prostate care. Instead of surgery or radiation, treatment is performed inside an MRI suite using robotically controlled, directional ultrasound to precisely ablate prostate tissue while protecting surrounding structures. TULSA-PRO is the only AI-powered, MR-guided robotic system for prostate therapy, enabling real-time MRI thermography and autonomous temperature control. This allows physicians to see, monitor and adjust treatment throughout the procedure — delivering personalized therapy with exceptional precision.\n \n\n \"Our exclusive partnership with Profound Medical marks a significant step in advancing precision prostate care across Australia and New Zealand,” commented Getz Healthcare ANZ Managing Director, Derek Foltin. “The TULSA-PRO system strengthens our commitment to deliver innovative, clinically proven technologies that improve patient outcomes and further advances our position in prostate cancer surgery and minimally invasive therapies.”\n \n\n “Like in many other regions around the globe, prostate cancer is the most commonly diagnosed cancer in men in Australasia,” said Arun Menawat, Profound’s CEO and Chairman. “We are excited to gain access to this significant market for TULSA-PRO. Beyond Australia and New Zealand, we are actively pursuing other potential opportunities to expand our strategic commercial partnership with Getz Healthcare to include additional key markets across Asia Pacific.”\n \n\n As user interest in Pr...